clinical trial · NCT05524571
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Immunovant Sciences GmbH·phase3·completed·n = 86
Thyroid Eye DiseaseBatoclimabPlacebo
brief summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
started
Jan 5, 2023
primary completion
Feb 3, 2026
completion
Mar 3, 2026
last updated
Apr 1, 2026
official title
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol